Fundies.
English

Segment disclosures

Company overview

Menlo Therapeutics Inc.

Each reported dimension combination stays separate. Revenue and operating income are shown as reported, with their dates and sources.

Revenue · Reported segment facts

1 dimension combinations 12 retained observations 9 reported periods

Counts describe retained dimensioned rows only. Periods and members can change across reports, and this view does not infer missing values or expected segment totals.

Royalty · Reportable Segment

Product Or Service · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=us-gaap:RoyaltyMember;us-gaap:StatementBusinessSegmentsAxis=vyne:ReportableSegmentMember
PeriodValueUnitFiledEvidence
2026-04-01 – 2026-06-3097000 USD20260813Open filing evidence
2026-01-01 – 2026-06-30183000 USD20260813Open filing evidence
2026-01-01 – 2026-03-3186000 USD20260515Open filing evidence
2025-01-01 – 2025-12-31570000 USD20260227Open filing evidence
2025-04-01 – 2025-06-3069000 USD20260813Open filing evidence
2025-01-01 – 2025-06-30271000 USD20260813Open filing evidence
2025-01-01 – 2025-03-31202000 USD20260515Open filing evidence
2024-01-01 – 2024-12-31501000 USD20260227Open filing evidence
2024-04-01 – 2024-06-30198000 USD20250814Open filing evidence
2024-01-01 – 2024-06-30296000 USD20250814Open filing evidence
2024-01-01 – 2024-03-3198000 USD20250508Open filing evidence
2023-01-01 – 2023-12-31424000 USD20250306Open filing evidence